C. Pichard

Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation

P. Kelly, S. Jeay, M. Llovera, 2000, Oncogene.

From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models.

P. Kelly, C. Bole-Feysot, M. Edery, 1999, Genetic analysis : biomolecular engineering.

A balanced deoxyribonucleoside mixture increased the rate of DNA incorporation of 5-[125I]Iodo-2'-deoxyuridine in glioblastoma cells.

Y. Dupertuis, F. Buchegger, C. Pichard, 2003, Cancer biotherapy & radiopharmaceuticals.

Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine.

Y. Dupertuis, D. Slosman, N. de Tribolet, 2001, Cancer research.

Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women.

C. Rousset-Jablonski, E. Larger, A. Plessier, 2021, Clinics and research in hepatology and gastroenterology.

Should prolactin be reconsidered as a therapeutic target in human breast cancer?

P. Kelly, V. Goffin, C. Pichard, 1999, Molecular and Cellular Endocrinology.

New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype.

E. Milgrom, P. Touraine, B. Paniel, 1999, Molecular endocrinology.